BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33593381)

  • 1. A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.
    Yu J; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    J Transl Med; 2021 Feb; 19(1):75. PubMed ID: 33593381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
    Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
    Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
    Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
    Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races.
    Wu P; Wu SG; He ZY
    Clin Breast Cancer; 2024 Feb; 24(2):e61-e70.e3. PubMed ID: 38007348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
    Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
    Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
    Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
    Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer.
    Lee YJ; Hwang YS; Kim J; Ahn SH; Son BH; Kim HJ; Ko BS; Kim J; Chung IY; Lee JW; Lee SB
    Sci Rep; 2021 Dec; 11(1):23509. PubMed ID: 34873249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
    Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
    Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction.
    Wang C; Xu Y; Lin Y; Zhou Y; Mao F; Zhang X; Shen S; Zhang Y; Sun Q
    Breast; 2022 Jun; 63():61-70. PubMed ID: 35334240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study.
    Zhang H; Xie P; Li Z; Huang R; Feng W; Kong Y; Xu F; Zhao L; Song Q; Li J; Zhang B; Fan J; Qiao Y; Xie X; Zheng S; He J; Wang K
    Diagn Pathol; 2019 May; 14(1):35. PubMed ID: 31054583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.
    Luo Y; Gao Y; Niu Z; Zhang J; Liu Z; Zhang Y; Shen S; Jiang Y; Xiao M; Zhu Q
    Quant Imaging Med Surg; 2024 May; 14(5):3519-3533. PubMed ID: 38720854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment and validation of a predictive nomogram model for advanced gastric cancer with perineural invasion].
    Liu SH; Hou XY; Zhang XX; Liu GW; Xin FJ; Wang JG; Zhang DL; Wang DS; Lu Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1059-1066. PubMed ID: 33212554
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study.
    Hou N; Xiao J; Wang Z; Wu Y; Hou G; Guo L; Zhang J; Ling R
    Clin Breast Cancer; 2020 Dec; 20(6):e682-e694. PubMed ID: 32713825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients.
    Pan B; Xu Y; Yao R; Cao X; Zhou X; Hao Z; Zhang Y; Wang C; Shen S; Luo Y; Zhu Q; Ren X; Kong L; Zhou Y; Sun Q
    J Transl Med; 2023 Nov; 21(1):798. PubMed ID: 37946210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk factor analysis on anastomotic leakage after laparoscopic surgery in rectal cancer patient with neoadjuvant therapy and establishment of a nomogram prediction model].
    Jiang W; Feng MY; Dong XY; Dong SM; Zheng JX; Liu XM; Liu WJ; Yan J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Aug; 22(8):748-754. PubMed ID: 31422613
    [No Abstract]   [Full Text] [Related]  

  • 16. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.
    Park YH; Im SA; Cho EY; Ahn JH; Woo SY; Kim S; Keam B; Lee JE; Han W; Nam SJ; Park IA; Noh DY; Yang JH; Ahn JS; Im YH
    Oncology; 2014; 86(5-6):279-88. PubMed ID: 24903080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
    Fan Y; Wang Y; He L; Imani S; Wen Q
    ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
    Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
    Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
    Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery.
    Jung JJ; Kang E; Kim EK; Kim SM; Jang M; La Yun B; Park SY; Shin HC
    Breast Cancer Res Treat; 2020 Sep; 183(2):373-380. PubMed ID: 32647937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.